Pfizer will buy Wyeth for $68 billion in cash and stock. The deal is intended to give Pfizer a broader product base, more geographical coverage, and an established biologics foundation to help it survive the loss of Lipitor’s exclusivity at the end of 2011. Said Jeffrey B. Kindler, Pfizer’s chairman and chief executive officer, “The combination of Pfizer and Wyeth provides a powerful opportunity to transform our industry. It will produce the world’s premier biopharmaceutical compa...